The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
Key Takeaways Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration (FDA) said Eli Lilly's ...
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...
The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...
The Medicine Foundry, which is expected to create 400 jobs, will be situated in the LEAP Research and Innovation District in ...
Eli Lilly (LLY) weight loss therapy tirzepatide is on track to launch across England’s National Health Service ((NHS)) as ...
"GMA" shares an exclusive look inside the lab of the maker of such drugs as Mounjaro and Zepbound to show what it's doing to ...
The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...
Eli Lilly said Wednesday it will invest $4.5 billion to build an advanced pharmaceutical drug manufacturing and development ...
Indianapolis-based Eli Lilly’s supply of Mounjaro, which is used to treat Type 2 diabetes, and popular weight-loss drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback